Current Report Filing (8-k)
May 08 2020 - 9:01AM
Edgar (US Regulatory)
false000167908200016790822020-05-042020-05-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2020
Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
Registrant’s telephone number, including area code: +44 207 400 3351
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On May 4, 2020, Kim Sablich, Chief Commercial Officer of Myovant Sciences, Inc., advised Myovant Sciences Ltd. that she was resigning from her position
to take on a senior executive role at a multinational pharmaceutical company. Ms. Sablich’s last day of employment is expected to be May 22, 2020.
Effective May 11, 2020, Adele Gulfo, Chief Business and Commercial Development Officer of Sumitovant Biopharma Inc. and board member of Myovant Sciences
Ltd., will assume the role of interim Chief Commercial Officer, assuming commercial leadership responsibilities. Prior to joining Sumitovant, Ms. Gulfo served as Chief of Commercial Development at Roivant Sciences. She also served as Chief Strategy
Officer, Executive Vice President, and Head of Global Commercial Development at Mylan, in addition to multiple executive leadership roles at Pfizer, including as President and General Manager of the U.S. primary care business unit. She has extensive
experience in building commercial organizations and has led the launches of multiple new products, including LIPITOR®.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Sep 2023 to Sep 2024